959992-62-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-3,4-dihydro-2H-pyrido[3,2-b]-1,4-oxazine is used as a starting material and building block for the development of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the synthesis of new drugs, potentially leading to the discovery of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 15128-82-2 3-hydroxy-2-nitropyridine 
• 443956-09-0 ethyl 2-(6-bromo-2-nitropyridin-3-yloxy)acetate 
• 1303588-62-6 C₇H₈Br₂N₂O 
• 443956-08-9 6-bromo-2-nitropyridin-3-ol 
• 959992-61-1 6-bromo-3-(2-bromoethoxy)-2-nitropyridine 
• 337463-88-4 6-bromo-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one 

Downstream Products

• 1303587-79-2 6-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1303587-91-8 (2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-yl)(6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methanone 
• 1303582-20-8 (2-(2,3-dihydroxypropoxy)pyridin-4-yl)(6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][l,4]oxazin-4(3H)-yl)methanone trifluoroacetate salt 
• 1303583-13-2 pyridin-3-yl 6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxylate 
• 1303581-80-7 N-(thiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide 
• 1214927-90-8 C₁₄H₁₂BrN₃O₂ 
• 1214928-52-5 C₂₀H₁₈N₄O₂ 
• 1214926-61-0 C₁₆H₁₅N₃O₄ 
• 1214926-59-6 C₁₅H₁₃N₃O₄ 
• 1214928-02-5 C₂₄H₂₂N₄O₅ 
• 1214928-16-1 C₂₂H₁₈N₄O₅ 
• 959992-64-4 tert-butyl 6-bromo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-carboxylate 
• 20348-23-6 3,4-dihydro-2H-pyrido[3,2-b ][1,4]oxazine 

Relevant academic research and scientific papers

Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof

The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.

TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR? AND THE TREATMENT OF DISEASE

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and relate

RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY

The present invention provides compounds or a pharmaceutically acceptable salt thereof which inhibit the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and are therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused morpholine compound shown in the present specification, or a pharmaceutically acceptable salt thereof.

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS

The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.

Alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.